API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
OTT166 (nesvategrast) is an investigational, patented, potent and selective RGD integrin inhibitor to regulate cellular responses to VEGF and other growth factors known to contribute to development and progression of diabetic retinopathy and other ocular diseases.
Lead Product(s): Nesvategrast
Therapeutic Area: Ophthalmology Product Name: OTT166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
OTT166 (nesvategrast) is a novel small molecule, potential first-in-class selective RGD integrin inhibitor specifically engineered for ocular delivery. It is under phase 2 clinical development for the treatment of diabetic retinopathy.
Lead Product(s): Nesvategrast
Therapeutic Area: Ophthalmology Product Name: OTT166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024